The initiative aimed to reach and support individuals suffering from epilepsy through early detection and effective disease management
Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine
Global Phase-3 study initiation expected in the second half of 2024
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
Dalal is an experienced leader at Abbott, having joined in 1995 as a Product Manager
AbCellera will receive an upfront payment and is eligible to receive additional milestone payments
The 200 bedded hospital owned & operated by Alexis
He is a former Neurology faculty member at The Johns Hopkins Hospital and an elected Fellow of the Royal College of Physicians, United Kingdom
Produodopa is the first-and-only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of severe motor fluctuations
The workshop was conducted as a part of the NITI–State workshop series
Subscribe To Our Newsletter & Stay Updated
